- Home
- LNN vs KNSA Comparison
LNN vs KNSA Comparison
Compare LNN & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNN
- KNSA
- Stock Information
- Founded
- LNN 1954
- KNSA 2015
- Country
- LNN United States
- KNSA United Kingdom
- Employees
- LNN N/A
- KNSA N/A
- Industry
- LNN Industrial Machinery/Components
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- LNN Industrials
- KNSA Health Care
- Exchange
- LNN Nasdaq
- KNSA Nasdaq
- Market Cap
- LNN 1.5B
- KNSA 1.7B
- IPO Year
- LNN 1988
- KNSA 2018
- Fundamental
- Price
- LNN $123.21
- KNSA $20.59
- Analyst Decision
- LNN Buy
- KNSA Strong Buy
- Analyst Count
- LNN 2
- KNSA 5
- Target Price
- LNN $132.00
- KNSA $36.60
- AVG Volume (30 Days)
- LNN 88.6K
- KNSA 290.2K
- Earning Date
- LNN 01-02-2025
- KNSA 10-29-2024
- Dividend Yield
- LNN 1.17%
- KNSA N/A
- EPS Growth
- LNN N/A
- KNSA N/A
- EPS
- LNN 6.01
- KNSA N/A
- Revenue
- LNN $607,074,000.00
- KNSA $384,098,000.00
- Revenue This Year
- LNN $10.09
- KNSA $60.05
- Revenue Next Year
- LNN $4.70
- KNSA $36.32
- P/E Ratio
- LNN $20.40
- KNSA N/A
- Revenue Growth
- LNN N/A
- KNSA 54.41
- 52 Week Low
- LNN $109.27
- KNSA $16.56
- 52 Week High
- LNN $135.20
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- LNN 42.21
- KNSA 40.95
- Support Level
- LNN $121.78
- KNSA $19.97
- Resistance Level
- LNN $131.70
- KNSA $20.85
- Average True Range (ATR)
- LNN 3.27
- KNSA 0.69
- MACD
- LNN -1.16
- KNSA 0.03
- Stochastic Oscillator
- LNN 21.95
- KNSA 35.61
About LNN Lindsay Corporation
Lindsay Corp provides various proprietary water management and road infrastructure products and services. It has operations categorized into two main reporting segments: Irrigation, and Infrastructure. The company generates maximum revenue from the Irrigation segment. Its Irrigation segment includes manufacturing and marketing center pivot, lateral move, and hose reel irrigation systems, as well as various technology solutions such as GPS positioning and guidance, variable rate irrigation, wireless irrigation management, M2M communication technology, and smartphone applications. Geographically, it derives a majority of its revenue from the United States.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.